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ABSTRACT: Amide- and ester-linked kinase inhibitor–cytotoxin conjugates were rationally designed and synthesised as prototype 
hypoxia-activated anticancer mutual prodrugs. Chemical reduction of an aryl nitro trigger moiety was shown to initiate a spontaneous 
cyclisation/fragmentation reaction that simultaneously released the kinase inhibitor semaxanib (SU5416) and the amine- or alcohol-
linked cytotoxin from the prodrugs. Preliminary cell testing and reduction potential measurements support optimisation of the com-
pounds towards tumour-selective mutual prodrugs. 
KEYWORDS: Hypoxia, mutual prodrug, anticancer, bioreductive activation,. Sunitinib, Semaxinib, Floxuridine, 4-aminoaniline 
mustard 
Cytotoxic drugs have been the mainstay of many anticancer treatment regimens but their effectiveness is limited by low 
tumour cell selectivity and, as a consequence, dose-limiting side effects. Tumour-activated prodrugs that selectively deliver 
cytotoxins to the immediate tumour microenvironment are sought as a means of improving the pharmacodynamics of cytotoxic 
drugs and reducing their toxicity towards non-cancerous tissues.1-4 Nitroaromatics have received intense study as prodrugs that 
can undergo reductive metabolism (bioactivation) to hydroxylamine or amine derivatives within the hypoxic environment of 
 
solid tumours.5-8 The newly revealed amine nucleophiles can then serve to trigger reactions that release the active cytotoxin. 
In 1994, the Denny group reported 2-nitrophenyl acetamides as hypoxia-activated prodrug scaffolds,9 where spontaneous cy-
clisation of the nascent 2-aminophenyl acetamide expelled an activated 4-aminoaniline mustard cytotoxin and an indoline-2-
one waste fragment. More recently, we reported the synthesis and anti-angiogenic properties of 2-nitrophenylacetate deriva-
tives related to the drug sunitinib (Sutent®), an indoline-2-one-based multi-kinase inhibitor used in the treatment of highly 
vascularised renal cell carcinomas and gastrointestinal stromal tumours (Figure 1(a)).10 
When considered in the context of Denny and colleagues’ work,9 we noted that our 2-nitrophenylacetates could potentially 
serve as tumor-activated ‘mutual’ prodrug scaffolds,11 wherein hypoxia-dependent bioactivation of the 2-nitrophenacetyl moi-
ety and ensuing cyclisation of the 2-aniline might simultaneously evolve an active cytotoxin (formerly incorporated within the 
prodrug as an amide or ester) along with the kinase inhibitor semaxanib (SU5416) 3, a clinically evaluated predecessor of 
sunitinib12-14 as a functionalised version of Denny’s indolin-2-one waste fragment. Furthermore, we noted that a hydrogen 
bond was invariably present between the pyrrole-NH and carbonyl oxygen atoms in our 2-nitrophenylacetic amides and esters 
(Figure 1(a)), suggesting the scaffold may be pre-organised and activated for rapid indoline-2-one cyclisation following reduc-
tion to the aniline.10 Conceptually, mutual prodrugs of this type could mitigate side effects arising from either or both drugs 







































































Figure 1. (a) Anti-angiogenic 2-nitrophenylacetate derivatives related to sunitinib.10 (b) Prototype mutual prodrugs 1 and 2 
and their proposed mechanism of bioreductive activation to selectively release the indoline-2-one kinase inhibitor semaxanib 
3 and 4-aminoaniline mustard or floxuridine cytotoxins within hypoxic regions of tumors. 
 
Two mutual prodrug prototypes were conceived to explore the concept. Prodrug 1 incorporated Denny’s 4-aminoaniline 
mustard linked to the 2-nitrophenylacetate scaffold via an amide (Figure 1(b)). In this compound, the amide would serve to 
withdraw electron density from the mustard nitrogen, thereby reducing DNA reactivity of the prodrug. The 4-aminoaniline 
mustard released into hypoxic tumors following prodrug activation would be vastly more DNA-reactive and cytotoxic due to 
increased electron density on the mustard nitrogen driving formation of DNA-alkylating aziridinium ions.9,15 Prodrug 2 linked 
the 2-nitrophenylacetate scaffold via an ester to the primary alcohol of the anticancer drug floxuridine (Figure 1(b)). As a 
nucleoside antimetabolite requiring phosphorylation as part of its mechanism, the drug should have reduced activity while 
tethered to the prodrug. Within normoxic tissues, the nitro radical anion intermediate formed on each prodrug following one-
electron reduction of the nitro group by human reductases is predicted to be back-scavenged by molecular oxygen, regenerating 
the prodrug. Within hypoxic tissues, further reduction of this intermediate to the amine 6-electron reduction product of each 
prodrug could occur, giving rise to hypoxia-selective triggering.16 
The synthesis of 1 commenced with the coupling of 2-nitrophenylacetic acid and p-phenylenediamine using 
HBTU/diisopropylethylamine to give 4 in 80% yield (Scheme 1). N,N-dialkylation of 4 with 2-bromoethanol in the presence 
of K2CO3 afforded bis-alcohol 5 in 62% yield. Mono-alkylation was achieved within hours but prolonged heating at 50 oC was 
required to obtain an acceptable yield of 5. Bis-alcohol protection of 5 using tert-butyldimethylsilyl chloride (TBDMSCl)/im-
idazole provided 6 in 86% yield. Reacting 6 with N-methylcarbamoyl pyrrole aldehyde 7 using our reported Knoevenagel 
conditions10 (K2CO3, 18-crown-6, THF, reflux) delivered the advanced precursor 8 in modest yield (21%) with no evidence of 
formation of the E-isomer in the 1H NMR spectrum of the crude reaction mixture. Despite trialling many other pyrrole pro-
tecting groups, bases, solvents and reaction conditions, the yield of 8 could not be improved. Performing the Knoevenagel 
reaction with 7 and unprotected 5 gave none of the desired bis-alcohol. Deprotection of 8 using TBAF buffered with acetic 
acid in THF at 0 °C delivered the bis-alcohol 9 in 86% yield. Final conversion to the target mustard 1 was accomplished in 
80% yield over 2 steps by first converting 9 to the bis-mesylate (MsCl, triethylamine) and then heating the freshly prepared 
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Scheme 1. Synthesis of mutual prodrug 1. 
The synthesis of 2 commenced with bis-TBS protection of the 1° and 2° alcohols of commercially available floxuridine 
(Scheme 2). The reaction proceeded well under standard conditions (TBDMSCl/imidazole) to give 10 in excellent yield (97%). 
Similarly high yields were previously reported for the bis-TBS protection of thymidine.17 Treatment of 10 with freshly distilled 
2,4-dimethoxybenzoyl chloride, diisopropylethylamine and DMAP gave the N-protected derivative 11 in 87% yield. Selective 
silyl-deprotection of the less hindered 1° alcohol using aqueous trichloroacetic acid (4.2 M) in THF (1:4)18 delivered 12 in 
50% yield. Steglich esterification19 of 12 with 2-nitrophenylacetic acid proceeded smoothly to give 13 (87%). Condensation 
of 13 with pyrrole aldehyde 7 using our Knoevenagel conditions10 produced a mixture of cis and trans isomers in modest yield 
((Z)-14 10%; (E)-14 11%). Extensive efforts to improve the yield were unsuccessful. Removal of the 2,4-dimethoxy benzoyl 
protecting group from (Z)-14 with ammonia in methanol gave the penultimate precursor 15 (75%) and final deprotection of 
the TBS group with TBAF/acetic acid delivered prodrug 2 (69%).20 Attempts to access the two prodrugs by an alternative route 
involving direct ester/amide coupling of cytotoxins to a 2-nitrophenylacetic acid derivative containing the pre-installed pyrrole 
group (obtained from the allyl ester in Figure 1(a)) were not successful, but led to the discovery of novel bioactive 3-imino-2-
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Scheme 2. Synthesis of mutual prodrug 2. 
Proof of concept reactions were performed with 1 and 2 to establish whether chemical reduction of the arylnitro groups 
would trigger spontaneous cyclisation of the nascent anilines to generate semaxanib 3 and, by inference, the respective 4-
aminoaniline mustard and floxuridine cytotoxins. Three standard room temperature arylnitro reduction reactions were em-
ployed: Fe/CH3COOH in EtOH/H2O,23 FeCl3.6H2O/Zn in DMF/H2O24 and NaBH4/Pd-C in MeOH/H2O25 (Table 1). Semaxanib 
3 was isolated from all reactions within 0.5-3 h in yields ranging from 37−84%. N-hydroxy semaxanib 16, formed by cyclisa-
tion of the intermediate N-hydroxylamine 4-electron reduction product, was also isolated from reactions in 11-51% yield. The 
combined yields of indoline-2-ones 3 and 16 were invariably high (80-94%) suggesting cyclisation within the scaffold is highly 
favoured. Downfield-shifting of the pyrrole-NH signals in the 1H NMR spectrum of 1 (δ 12.04 ppm) and 2 (δ 11.66 ppm) (and 
all pyrrole-containing intermediates) confirmed both cis stereochemistry for the compounds and the presence of an intramo-
lecular hydrogen bond between the pyrrole-NH and carbonyl oxygen atoms.10 This H-bond in 1 and 2 likely serves as a pseudo-
acid catalyst that promotes spontaneous cyclisation.  
 
































1 and 2  
Prodrug Reductant Solvent t (h) Yield 3 (%) Yield 16 (%) Yield 3+16 (%) 
1 Fe/CH3COOH EtOH/H2O 1 80 14 94 
 FeCl3.6H2O/Zn DMF/H2O 3 53 32 85 
 NaBH4/Pd-C MeOH/H2O 0.5 43 37 80 
2 Fe/CH3COOH EtOH/H2O 1 84 11 95 
 FeCl3.6H2O/Zn DMF/H2O 3 40 51 91 
 NaBH4/Pd-C MeOH/H2O 0.5 37 45 82 
 
Preliminary biological testing of 1 and 2 was carried out using MDA-MB-468 triple-negative breast cancer cells and SW620 
colon cancer cells (Table 2). The prodrugs were assessed first for their degree of deactivation relative to parent cytotoxin 
control compounds under aerobic conditions. For prodrug 1, melphalan was selected as the clinically relevant nitrogen mustard 
control26 and for prodrug 2 the comparator was Floxuridine. The degree of prodrug deactivation was determined using the 
deactivation ratio (DR = Aerobic IC50prodrug/Aerobic IC50control). For prodrug 1, 8.5-fold and 3.0-fold deactivation was observed 
in the two cell-lines, while 3.0-fold and 6.9-fold deactivation was seen with 2. It is proposed that for 1, the amide bond pulls 
electron density away from the mustard nitrogen leading to decreased DNA reactivity (and hence cytotoxicity) in the prodrug. 
In the case of 2, Floxuridine is an antimetabolite and would be inactivated by the ester linkage to the bulky 2-nitrophenylacetate 
moiety. The deactivation observed with prodrug 2 relative to floxuridine suggests that the ester bond remained intact under the 
assay conditions. The ability of the prodrugs to undergo nitroaromatic bioreduction and cyclisation to release the respective 
cytotoxins was determined using the hypoxic cytotoxicity ratio (HCR = Aerobic IC50/Anoxic IC50). Under the assay condi-




Table 2. Biological evaluation of mutual prodrugs. 
Cell line Drug Aero IC50 (µM) Anox IC50 (µM) DRa HCRb 
MDA-MB-468 Melphalan 1.00 ± 0.11 0.81 ± 0.16 - 1.2-fold 
 Floxuridine 27.42 ± 12.52 45.53 ± 6.10 - <1-fold  
 1 8.31 ± 0.95 7.38 ± 0.88 8.3-fold 1.1-fold 
 2 83.88 ± 40.93 247.96 ± 80.56 3.1-fold <1-fold 
 Tirapazamine 105.2 1.304 - 81-fold 
 TH-302 4.403 0.0062 - 710-fold 
SW620 Melphalan 1.81 ± 0.25 1.22 ± 0.10 - 1.5-fold 
 Floxuridine 0.96 ± 0.40 1.48 ± 0.53 - <1-fold 
 1 11.48 ± 6.57 12.67 ± 4.93 6.3-fold <1-fold 
 2 18.70 ± 14.81 13.96 ± 5.39 19.4-fold 1.3-fold 
 Tirapazamine 91.03 1.2 - 76-fold 
 TH-302 20.6 0.052 - 396-fold 
Sensitivity of MDA-MB-468 and SW620 cells to hypoxia-activated mutual prodrugs 1 and 2 and their parent cytotoxins under 
aerobic (Aero) and anoxic (Anox) conditions. Antiproliferative IC50 values are shown (mean ± std dev, n = 3). The activity of 
two positive control hypoxia-activated cytotoxins Tirapazamine27 and TH-30228 are included for comparison (n = 1). aThe 
deactivation ratio (DR) indicates the degree of deactivation of the prodrug relative to the effector under aerobic conditions (i.e. 
DR = Aero prodrug IC50/Aero control cytotoxin IC50). bThe hypoxic cytotoxicity ratio (HCR) indicates whether cells are 
more sensitive to the prodrugs or effectors under anoxic conditions (HCR = aerobic IC50/anoxic IC50). 
 
To examine why 1 and 2 did not show enhanced cytotoxicity under anoxia, one-electron reduction potentials (E[1]) for the 
arylnitro groups in the prodrugs were measured using pulse radiolysis. This thermodynamic parameter characterises the elec-
tron affinity of nitroaromatics and hence their willingness to accept an electron from human oxidoreductases. Pulse radiolysis 
of 2 returned E[1] = -509 ± 8 mV, but measurements for 1 were confounded by poor aqueous solubility. Measurements were 




arylnitro group would limit their influence on the reduction potential. Pulse radiolysis of 9 returned E[1] = -550 ± 8 mV. Thus, 
we conclude that the lack of bioreductive activation observed with the prodrugs under anoxia arises from the low nitroaromatic 
one-electron reduction potentials. It has been reported that nitroaromatic prodrugs show greatest hypoxia-selectivity when E[1] 
falls within the range -330 to -450 mV.2 With E[1] for 1 and 2 falling below this, the prodrugs are unable to accept electrons 
from one-electron reductases at appreciable rates and therefore incapable of undergoing bioreduction in cells under anoxia. 
In conclusion, we have rationally-designed and synthesized amide and ester-linked hypoxia-activated mutual prodrug pro-
totypes and provided chemical proof of concept showing that reduction of the arylnitro group triggers simultaneous release of 
two cancer drugs. Release of N-hydroxy semaxanib 16 was also noted but if generated in vivo, this compound could serve as 
an active kinase inhibitor, especially against VEGFR-2.29 Reduction potentials in the prototypes are at this stage too low to 
confer efficient bioreductive activation. Appending electron withdrawing groups to the nitroaryl ring could increase the reduc-
tion potential towards the target minimum of -450 mV. Attaching electron withdrawing groups to the indoline-2-one of Se-
maxinib is known to produce only minor changes in kinase inhibition.30 Additionally, Denny showed that electron withdrawing 
groups do not affect cyclisation rates of 2-aminophenyl acetamides formed by reduction of 2-nitrophenyl acetamide prodrugs.9 
Based on this, a second generation of compounds containing electron withdrawing groups on the nitroaryl ring are the focus 
of efforts to optimise the mutual prodrugs for clinical use. 
 
Appendix A. Supplementary data 
Synthesis, compound characterisation and 1H NMR/13C NMR spectra for compounds 1, 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, (Z)-
14, (E)-14, 15. Chemical reductions, pulse radiolysis experiments and in vitro cell experiments. The Supplementary Data is 
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